INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. ACN
7. IBM
8. NKE
9. MU
10. AWK

Go back to INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
(NASDAQ: INMB) Delayed: 1.42 -0.01 (0.7%)
Previous Close $1.43    52 Week High $ 
Open $1.39    52 Week Low $ 
Day High $1.50    P/E N/A 
Day Low $1.39    EPS $ 
Volume 432,229       

(NASDAQ: INMB) Delayed: 1.42 -0.01 (0.7%)
Previous Close $1.43    52 Week High $ 
Open $1.39    52 Week Low $ 
Day High $1.50    P/E N/A 
Day Low $1.39    EPS $ 
Volume 432,229